

Emanuel Raschi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7414223/publications.pdf>

Version: 2024-02-01

154
papers

3,801
citations

159525

30
h-index

182361

51
g-index

157
all docs

157
docs citations

157
times ranked

5186
citing authors

#	ARTICLE	IF	CITATIONS
1	The β -adrenoceptor as a therapeutic target: Current perspectives. <i>Pharmacological Research</i> , 2009, 59, 221-234.	3.1	143
2	The hERG K ⁺ channel: target and antitarget strategies in drug development. <i>Pharmacological Research</i> , 2008, 57, 181-195.	3.1	131
3	Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. , 2010, 125, 196-218.		126
4	Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 512-518.	0.9	121
5	Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: Systematic review of observational studies. <i>Cephalalgia</i> , 2015, 35, 118-131.	1.8	115
6	Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective. <i>Current Medicinal Chemistry</i> , 2013, 21, 417-436.	1.2	109
7	Antimicrobials and the Risk of Torsades de Pointes. <i>Drug Safety</i> , 2010, 33, 303-314.	1.4	108
8	The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. <i>Acta Diabetologica</i> , 2013, 50, 569-577.	1.2	101
9	Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS). , 0, , .		98
10	Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. <i>Targeted Oncology</i> , 2020, 15, 449-466.	1.7	86
11	COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety. <i>Drug Safety</i> , 2021, 44, 1247-1269.	1.4	85
12	Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 533-542.	1.1	83
13	Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System. <i>International Journal of Cardiology</i> , 2018, 273, 183-186.	0.8	78
14	Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. <i>Targeted Oncology</i> , 2019, 14, 205-221.	1.7	72
15	hERG-related drug toxicity and models for predicting hERG liability and QT prolongation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 1005-1021.	1.5	70
16	Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. <i>BMJ, The</i> , 2016, 353, i2231.	3.0	70
17	Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 306-314.	2.3	67
18	Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 894-908.	1.1	67

#	ARTICLE	IF	CITATIONS
19	Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 285-293.	1.1	66
20	Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System. <i>Psychotherapy and Psychosomatics</i> , 2021, 90, 41-48.	4.0	63
21	Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database. <i>Drug Safety</i> , 2013, 36, 467-479.	1.4	61
22	Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 219-227.	1.1	59
23	Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. <i>World Journal of Hepatology</i> , 2014, 6, 601.	0.8	59
24	Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology. <i>Internal and Emergency Medicine</i> , 2012, 7, 113-131.	1.0	49
25	Pro-Arrhythmic Potential of Oral Antihistamines (H1): Combining Adverse Event Reports with Drug Utilization Data across Europe. <i>PLoS ONE</i> , 2015, 10, e0119551.	1.1	49
26	Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe. <i>PLoS ONE</i> , 2013, 8, e81208.	1.1	45
27	Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1533-1540.	1.1	40
28	Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk. <i>World Journal of Hepatology</i> , 2015, 7, 1761.	0.8	40
29	ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance. <i>EClinicalMedicine</i> , 2021, 38, 101027.	3.2	39
30	Hepatitis B vaccination and the putative risk of central demyelinating diseases – A systematic review and meta-analysis. <i>Vaccine</i> , 2018, 36, 1548-1555.	1.7	37
31	Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications. <i>BMC Medicine</i> , 2014, 12, 98.	2.3	35
32	SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system. <i>Cardiovascular Diabetology</i> , 2021, 20, 39.	2.7	35
33	Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones. <i>Drug Safety</i> , 2012, 35, 315-323.	1.4	34
34	Human papillomavirus vaccine and demyelinating diseases – A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2018, 132, 108-118.	3.1	32
35	Risk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies. <i>Drug Safety</i> , 2016, 39, 1175-1187.	1.4	31
36	Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 1098-1107.	1.1	31

#	ARTICLE	IF	CITATIONS
37	Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 380-386.	1.1	30
38	Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System. <i>Oncologist</i> , 2019, 24, e1228-e1231.	1.9	30
39	Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection. <i>Drug Safety</i> , 2015, 38, 535-551.	1.4	29
40	Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 983-989.	0.8	29
41	Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues. <i>Pharmaceuticals</i> , 2021, 14, 738.	1.7	29
42	Clinically important drug-drug interactions in poly-treated elderly outpatients: a campaign to improve appropriateness in general practice. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1411-1420.	1.1	27
43	Evolving Roles of Spontaneous Reporting Systems to Assess and Monitor Drug Safety. , 0, , .		26
44	Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000725.	1.2	26
45	The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project. <i>Drug Safety</i> , 2016, 39, 59-68.	1.4	25
46	Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis. <i>Drug Safety</i> , 2020, 43, 1277-1285.	1.4	25
47	Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella review. <i>European Journal of Internal Medicine</i> , 2020, 75, 60-70.	1.0	25
48	Identification of Drug Interaction Adverse Events in Patients With COVID-19. <i>JAMA Network Open</i> , 2022, 5, e227970.	2.8	25
49	Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems. <i>Drug Safety</i> , 2018, 41, 745-752.	1.4	24
50	Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors. <i>Frontiers in Pharmacology</i> , 2019, 10, 1235.	1.6	24
51	Appropriateness of Proton Pump Inhibitor prescription in patients admitted to hospital: Attitudes of general practitioners and hospital physicians in Italy. <i>European Journal of Internal Medicine</i> , 2016, 30, 31-36.	1.0	23
52	Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 233-239.	0.8	23
53	Drug-induced liver injury: Towards early prediction and risk stratification. <i>World Journal of Hepatology</i> , 2017, 9, 30.	0.8	22
54	Recurrence of pericarditis after influenza vaccination: a case report and review of the literature. <i>BMC Pharmacology & Toxicology</i> , 2018, 19, 20.	1.0	22

#	ARTICLE	IF	CITATIONS
55	ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations. <i>Internal and Emergency Medicine</i> , 2018, 13, 1-9.	1.0	21
56	Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1633-1640.	1.4	21
57	Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System. <i>Cancers</i> , 2021, 13, 1758.	1.7	19
58	Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1903-1914.	0.9	18
59	Observational research on sodium glucose co-transporter ² inhibitors: A real breakthrough?. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2711-2723.	2.2	18
60	Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system. <i>Acta Diabetologica</i> , 2020, 57, 71-80.	1.2	18
61	Assessment of adverse reactions to α -lipoic acid containing dietary supplements through spontaneous reporting systems. <i>Clinical Nutrition</i> , 2021, 40, 1176-1185.	2.3	18
62	Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 247-255.	3.3	18
63	Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database. <i>Drug Safety</i> , 2022, 45, 891-908.	1.4	18
64	Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 88-98.	1.1	17
65	Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 293-305.	1.5	17
66	The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia. <i>Current Heart Failure Reports</i> , 2020, 17, 365-383.	1.3	17
67	Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1334-1342.	0.8	16
68	Role of drugs and devices in patients at risk of sudden cardiac death. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 575-594.	1.0	15
69	Pattern of drug use among preterm neonates: results from an Italian neonatal intensive care unit. <i>Italian Journal of Pediatrics</i> , 2017, 43, 37.	1.0	15
70	Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e120-e120.	0.5	15
71	DPP-4 inhibitors and venous thromboembolism: an analysis of the WHO spontaneous reporting database. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 365-367.	5.5	15
72	Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 727-736.	1.0	15

#	ARTICLE	IF	CITATIONS
73	Generic atypical antipsychotic drugs in Belgium: their influence and implications. <i>Journal of Comparative Effectiveness Research</i> , 2013, 2, 551-561.	0.6	14
74	Potential to Enhance the Prescribing of Generic Drugs in Patients with Mental Health Problems in Austria; Implications for the Future. <i>Frontiers in Pharmacology</i> , 2012, 3, 198.	1.6	13
75	Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews. <i>Drug Safety</i> , 2019, 42, 1409-1422.	1.4	13
76	Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative database. <i>Aging</i> , 2020, 12, 19711-19739.	1.4	13
77	Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications. <i>International Journal of Clinical Practice</i> , 2013, 67, 170-180.	0.8	12
78	Pharmacological prioritisation of signals of disproportionate reporting: proposal of an algorithm and pilot evaluation. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 617-625.	0.8	12
79	Comparing the Prevalence of Polypharmacy and Potential Drug-Drug Interactions in Nursing Homes and in the Community Dwelling Elderly of Emilia Romagna Region. <i>Frontiers in Pharmacology</i> , 2020, 11, 624888.	1.6	12
80	Prevalence and Determinants of Long-Term Utilization of Antidepressant Drugs: A Retrospective Cohort Study. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 1157-1170.	1.0	12
81	Targeting the Arrhythmogenic Substrate in Atrial Fibrillation: Focus on Structural Remodeling. <i>Current Drug Targets</i> , 2011, 12, 263-286.	1.0	11
82	Emerging therapeutic uses of direct-acting oral anticoagulants: An evidence-based perspective. <i>Pharmacological Research</i> , 2017, 120, 206-218.	3.1	11
83	Evidence for the hERG Liability of Antihistamines, Antipsychotics, and Anti-infective Agents: A Systematic Literature Review From the ARITMO Project. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 558-572.	1.0	11
84	Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1367-1369.	1.0	11
85	Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. <i>Vaccines</i> , 2021, 9, 19.	2.1	11
86	Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis. <i>International Journal of Cancer</i> , 2021, 149, 675-683.	2.3	11
87	Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 3391-3409.	2.0	11
88	Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System. <i>Targeted Oncology</i> , 2022, 17, 43-51.	1.7	11
89	Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical Practice. <i>Drug Safety</i> , 2017, 40, 461-464.	1.4	10
90	Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 869-874.	1.0	10

#	ARTICLE	IF	CITATIONS
91	Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 199-205.	1.3	10
92	Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: beyond bleeding complications. <i>Polish Archives of Internal Medicine</i> , 2016, 126, 552-561.	0.3	10
93	Reporting of immune checkpoint inhibitor-associated myocarditis. <i>Lancet, The</i> , 2018, 392, 383.	6.3	9
94	Drug-induced Kounis syndrome: A matter of pharmacovigilance. <i>International Journal of Cardiology</i> , 2019, 274, 381.	0.8	9
95	Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance. <i>Drug Safety</i> , 2020, 43, 1191-1194.	1.4	9
96	The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice. <i>British Journal of Dermatology</i> , 2021, 184, 581-583.	1.4	9
97	Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1421-1431.	1.0	9
98	Mesenchymal stromal cell-based therapy: Regulatory and translational aspects in gastroenterology. <i>World Journal of Gastroenterology</i> , 2016, 22, 9057.	1.4	9
99	Can authorities take advantage of the availability of generic atypical antipsychotic drugs? Findings from Sweden and potential implications. <i>Journal of Pharmaceutical Health Services Research</i> , 2013, 4, 139-150.	0.3	8
100	Drug-induced renal injury in neonates: challenges in clinical practice and perspectives in drug development. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 555-565.	1.5	8
101	Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review. <i>Clinical Drug Investigation</i> , 2020, 40, 1001-1008.	1.1	8
102	Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1169-1176.	1.3	8
103	Conceiving, conducting, reporting, interpreting, and publishing disproportionality analyses: A call to action. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3535-3536.	1.1	8
104	QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 839-841.	1.1	7
105	No signal of interactions between influenza vaccines and drugs used for chronic diseases: a case-by-case analysis of the vaccine adverse event reporting system and viginbase. <i>Expert Review of Vaccines</i> , 2018, 17, 363-381.	2.0	7
106	Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System. <i>Drug Safety</i> , 2022, 45, 663-673.	1.4	7
107	The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3107-e3114.	1.8	7
108	Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 715-720.	0.8	6

#	ARTICLE	IF	CITATIONS
109	Use of phytoestrogens and effects perceived by postmenopausal women: result of a questionnaire-based survey. <i>BMC Complementary and Alternative Medicine</i> , 2014, 14, 262.	3.7	6
110	Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping. <i>Drug Safety</i> , 2017, 40, 823-834.	1.4	6
111	Advancements in drug development for diarrhea-predominant irritable bowel syndrome. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 251-263.	1.9	6
112	TELEmedicine for EPilepsy Care (TELE-EPIC): protocol of a randomised, open controlled non-inferiority clinical trial. <i>BMJ Open</i> , 2021, 11, e053980.	0.8	6
113	ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectationsâ€”authorsâ€™ reply. <i>Internal and Emergency Medicine</i> , 2018, 13, 635-636.	1.0	5
114	Relationship between adverse drug reactions to antibacterial agents and the <i>Klebsiella pneumoniae</i> carbapenemase-producing (KPC) <i>Klebsiella pneumoniae</i> outbreak: insight from a pharmacovigilance study. <i>BMC Pharmacology & Toxicology</i> , 2019, 20, 65.	1.0	5
115	Impulsive conditions in Parkinson's disease: A pharmacosurveillance-supported list. <i>Parkinsonism and Related Disorders</i> , 2021, 90, 79-83.	1.1	5
116	Impact of nephrotoxic drugs on urinary biomarkers of renal function in very preterm infants. <i>Pediatric Research</i> , 2022, 91, 1715-1722.	1.1	5
117	Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System. <i>Frontiers in Pharmacology</i> , 2021, 12, 740707.	1.6	5
118	Liver Injury with Nintedanib: A Pharmacovigilanceâ€”Pharmacokinetic Appraisal. <i>Pharmaceuticals</i> , 2022, 15, 645.	1.7	5
119	Comment on: â€œPharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitusâ€. <i>Clinical Pharmacokinetics</i> , 2015, 54, 447-448.	1.6	4
120	Safety Meta-Analysis. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2193.	1.2	4
121	Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon?. <i>Internal and Emergency Medicine</i> , 2017, 12, 923-934.	1.0	4
122	Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1087-1090.	0.9	4
123	Signal of potentially protective drugâ€”drug interactions from spontaneous reporting systems: proceed with caution. <i>Acta Diabetologica</i> , 2020, 57, 115-116.	1.2	4
124	Reduced neuropsychiatric events as â€œbeneficial reactionsâ€ to drugs: Seek associations with caution. <i>Brain, Behavior, and Immunity</i> , 2020, 84, 275-276.	2.0	4
125	DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus. <i>Drug Safety</i> , 2020, 43, 767-774.	1.4	4
126	Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems. <i>Journal of Nephrology</i> , 2022, 35, 1017-1027.	0.9	4

#	ARTICLE	IF	CITATIONS
127	Liver injury with direct-acting anticoagulants: has the fog cleared?. Heart, 2017, 103, 2010-2010.	1.2	3
128	Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres. PLoS ONE, 2019, 14, e0211938.	1.1	3
129	The safety of available treatment options for short bowel syndrome and unmet needs. Expert Opinion on Drug Safety, 2021, 20, 1501-1513.	1.0	3
130	Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis. Mycoses, 2021, 64, 1317-1327.	1.8	3
131	Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry. Kidney International Reports, 2021, 6, 2472-2477.	0.4	3
132	Liver injury with dipeptidyl peptidase-4 (DPP-4) inhibitors (GLIPTINS): signals emerging from the us-fda adverse event reporting system. Clinical Therapeutics, 2015, 37, e106.	1.1	2
133	Drug utilization research and pharmacovigilance. , 2016, , 399-407.		2
134	Balancing the Need for Personalization of QT Correction and Generalization of Study Results: Going Beyond Thorough QT Studies. Clinical Drug Investigation, 2017, 37, 985-988.	1.1	2
135	Risk of bradyarrhythmia related to ticagrelor: A systematic review and meta-analysis. Pharmacological Research, 2020, 160, 105089.	3.1	2
136	Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e430-e431.	1.3	2
137	Macrolides and Torsadogenic Risk: Emerging Issues from the FDA Pharmacovigilance Database. Journal of Pharmacovigilance, 2013, 01, .	0.2	2
138	Glucagon-like Peptide 1-Based Drugs and Pancreatic Safety. JAMA Internal Medicine, 2013, 173, 1843.	2.6	1
139	Hospitalisations by Drug interactions with nsaid in elderly poly-treated patients: outcome research on administrative databases. Clinical Therapeutics, 2015, 37, e101-e102.	1.1	1
140	Stroke, Migraine and Triptans: From Bedside to Bench. EBioMedicine, 2016, 6, 14-15.	2.7	1
141	Switching among Equivalents in Chronic Cardiovascular Therapies: "Real World" Data from Italy. Basic and Clinical Pharmacology and Toxicology, 2016, 118, 63-69.	1.2	1
142	Association between the use of proton pump inhibitors and cardiovascular events: A note of caution. Neurogastroenterology and Motility, 2017, 29, e12977.	1.6	1
143	SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?. Expert Opinion on Pharmacotherapy, 2021, 22, 647-650.	0.9	1
144	Authors' Reply to Robert P. Giugliano and Colleagues' Comment on: "Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance". Drug Safety, 2021, 44, 505-506.	1.4	1

#	ARTICLE	IF	CITATIONS
145	Reply-Letter to the editor - The valuable support of spontaneous reporting systems in exploring safety profile of dietary supplements. <i>Clinical Nutrition</i> , 2020, 39, 3854-3855.	2.3	1
146	Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 303-320.	0.9	1
147	Reply to the Comments by Doherty et al.. <i>Psychotherapy and Psychosomatics</i> , 2021, 90, 140-141.	4.0	1
148	Authors'™ reply to Tufan and colleagues and Boucaud-Maitre. <i>BMJ, The</i> , 2016, 353, i3188.	3.0	0
149	Authors'™ Reply to Alain Braillon's™ Comment on "The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project", <i>Drug Safety</i> , 2016, 39, 367-368.	1.4	0
150	Safety Profile of Sodium-Glucose Co-Transporter-2 Inhibitors: A Global Analysis of Pharmacovigilance Databases. <i>Clinical Therapeutics</i> , 2017, 39, e38-e39.	1.1	0
151	Fluoroquinolones and Aortic Disease. <i>JAMA Internal Medicine</i> , 2021, 181, 881.	2.6	0
152	Risk-Benefit Profile of Novel Anti-diabetic Drugs: Current Perspectives. <i>Journal of Pharmacovigilance</i> , 2016, 4, .	0.2	0
153	Safety of esketamine nasal spray: Analysis of post-marketing reports submitted to the FDA adverse event reporting system in the first year on the market. <i>European Psychiatry</i> , 2021, 64, S150-S151.	0.1	0
154	Letter to the editor: RECAM for the diagnosis of DILI"Is it time to incorporate additional pharmacological criteria?. <i>Hepatology</i> , 2022, 76, E25-E26.	3.6	0